|
1
|
Rajabi P, Bagheri M and Hani M: Expression
of estrogen receptor alpha in malignant melanoma. Adv Biomed Res.
6:142017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Girotti MR, Gremel G, Lee R, Galvani E,
Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, et
al: Application of sequencing, liquid biopsies, and patient-derived
xenografts for personalized medicine in melanoma. Cancer Discov.
6:286–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hopfner R, Mousli M, Jeltsch JM, Voulgaris
A, Lutz Y, Marin C, Bellocq JP, Oudet P and Bronner C: ICBP90, a
novel human CCAAT binding protein, involved in the regulation of
topoisomerase IIalpha expression. Cancer Res. 60:121–128.
2000.PubMed/NCBI
|
|
4
|
Bronner C, Krifa M and Mousli M:
Increasing role of UHRF1 in the reading and inheritance of the
epigenetic code as well as in tumorogenesis. Biochem Pharmacol.
86:1643–1649. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim JK, Estève PO, Jacobsen SE and Pradhan
S: UHRF1 binds G9a and participates in p21 transcriptional
regulation in mammalian cells. Nucleic Acids Res. 37:493–505. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bronner C, Fuhrmann G, Chédin FL, Macaluso
M and Dhe-Paganon S: UHRF1 links the histone code and DNA
methylation to ensure faithful epigenetic memory inheritance. Genet
Epigenet. 2009:29–36. 2010.PubMed/NCBI
|
|
7
|
Unoki M, Daigo Y, Koinuma J, Tsuchiya E,
Hamamoto R and Nakamura Y: UHRF1 is a novel diagnostic marker of
lung cancer. Br J Cancer. 103:217–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Unoki M, Nishidate T and Nakamura Y:
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG
through its SRA domain. Oncogene. 23:7601–7610. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang GL, Zhang LH, Bo JJ, Chen HG, Cao M,
Liu DM and Huang YR: UHRF1 is associated with tumor recurrence in
non-muscle-invasive bladder cancer. Med Oncol. 29:842–847. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liang D, Xue H, Yu Y, Lv F, You W and
Zhang B: Elevated expression of UHRF1 predicts unfavorable
prognosis for patients with hepatocellular carcinoma. Int J Clin
Exp Pathol. 8:9416–9421. 2015.PubMed/NCBI
|
|
11
|
Yan F, Tan XY, Geng Y, Ju HX, Gao YF and
Zhu MC: Inhibition effect of siRNA-downregulated UHRF1 on breast
cancer growth. Cancer Biother Radiopharm. 26:183–189. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan F, Wang X, Shao L, Ge M and Hu X:
Analysis of UHRF1 expression in human ovarian cancer tissues and
its regulation in cancer cell growth. Tumour Biol. 36:8887–8893.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kallioniemi OP, Wagner U, Kononen J and
Sauter G: Tissue microarray technology for high-throughput
molecular profiling of cancer. Hum Mol Genet. 10:657–662. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang JH, Gao Q, Ke AW, Yu Y, Shi GM, Fan
J, Zhou J and Huang XW: Prognostic significance of nuclear RNA
export factor 3 in hepatocellular carcinoma. Oncol Lett. 7:641–646.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(Review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mousli M, Hopfner R, Abbady AQ, Monté D,
Jeanblanc M, Oudet P, Louis B and Bronner C: ICBP90 belongs to a
new family of proteins with an expression that is deregulated in
cancer cells. Br J Cancer. 89:120–127. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang P, Cheng CL, Chang YH, Liu CH, Hsu
YC, Chen JS, Chang GC, Ho BC, Su KY, Chen HY and Yu SL: Molecular
gene signature and prognosis of non-small cell lung cancer.
Oncotarget. 7:51898–51907. 2016.PubMed/NCBI
|
|
20
|
Liu X, Ou H, Xiang L, Li X, Huang Y and
Yang D: Elevated UHRF1 expression contributes to poor prognosis by
promoting cell proliferation and metastasis in hepatocellular
carcinoma. Oncotarget. 8:10510–10522. 2017.PubMed/NCBI
|
|
21
|
Geng Y, Gao Y, Ju H and Yan F: Diagnostic
and prognostic value of plasma and tissue ubiquitin-like,
containing PHD and RING finger domains 1 in breast cancer patients.
Cancer Sci. 104:194–199. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ashraf W, Ibrahim A, Alhosin M, Zaayter L,
Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C and
Mousli M: The epigenetic integrator UHRF1: On the road to become a
universal biomarker for cancer. Oncotarget. 8:51946–51962. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bronner C, Achour M, Arima Y, Chataigneau
T, Saya H and Schini-Kerth VB: The UHRF family: Oncogenes that are
drugable targets for cancer therapy in the near future? Pharmacol
Ther. 115:419–434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang F, Yang YZ, Shi CZ, Zhang P, Moyer
MP, Zhang HZ, Zou Y and Qin HL: UHRF1 promotes cell growth and
metastasis through repression of p16ink4a in colorectal
cancer. Ann Surg Oncol. 19:2753–2762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kashani-Sabet M, Rangel J, Torabian S,
Nosrati M, Simko J, Jablons DM, Moore DH, Haqq C, Miller JR III and
Sagebiel RW: A multi-marker assay to distinguish malignant
melanomas from benign nevi. Proc Natl Acad Sci USA. 106:6268–6272.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Achour M, Mousli M, Alhosin M, Ibrahim A,
Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S and
Bronner C: Epigallocatechin-3-gallate up-regulates tumor suppressor
gene expression via a reactive oxygen species-dependent
down-regulation of UHRF1. Biochem Biophys Res Commun. 430:208–212.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alhosin M, Sharif T, Mousli M,
Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB and Bronner C:
Down-regulation of UHRF1, associated with re-expression of tumor
suppressor genes, is a common feature of natural compounds
exhibiting anti-cancer properties. J Exp Clin Cancer Res.
30:412011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fang L, Shanqu L, Ping G, Ting H, Xi W, Ke
D, Min L, Junxia W and Huizhong Z: Gene therapy with RNAi targeting
UHRF1 driven by tumor-specific promoter inhibits tumor growth and
enhances the sensitivity of chemotherapeutic drug in breast cancer
in vitro and in vivo. Cancer Chemother Pharmacol. 69:1079–1087.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guerriere-Kovach PM, Hunt EL, Patterson
JW, Glembocki DJ, English JC III and Wick MR: Primary melanoma of
the skin and cutaneous melanomatous metastases: Comparative
histologic features and immunophenotypes. Am J Clin Pathol.
122:70–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Kempen LC, van den Oord JJ, van Muijen
GN, Weidle UH, Bloemers HP and Swart GW: Activated leukocyte cell
adhesion molecule/CD166, a marker of tumor progression in primary
malignant melanoma of the skin. Am J Pathol. 156:769–774. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhu Isabel Y and Fitzpatrick JE:
Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
J Cutan Pathol. 33:33–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rosner K, Mehregan DR, Moussai D, Abrams
J, Tromp G and Mehregan DA: WT1 marker is not sufficient for
distinguishing between melanoma and melanocytic nevi. J Cutan
Pathol. 36:1077–1082. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fullen DR, Reed JA, Finnerty B and McNutt
NS: S100A6 preferentially labels type C nevus cells and nevic
corpuscles: Additional support for Schwannian differentiation of
intradermal nevi. J Cutan Pathol. 28:393–399. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Busam KJ, Chen YT, Old LJ, Stockert E,
Iversen K, Coplan KA, Rosai J, Barnhill RL and Jungbluth AA:
Expression of melan-A (MART1) in benign melanocytic nevi and
primary cutaneous malignant melanoma. Am J Surg Pathol. 22:976–982.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kucher C, Zhang PJ, Pasha T, Elenitsas R,
Wu H, Ming ME, Elder DE and Xu X: Expression of Melan-A and Ki-67
in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol.
26:452–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haqq C, Nosrati M, Sudilovsky D, Crothers
J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR III, Allen RE,
Singer MI, et al: The gene expression signatures of melanoma
progression. Proc Natl Acad Sci USA. 102:6092–6097. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Crnogorac-Jurcevic T, Gangeswaran R,
Bhakta V, Capurso G, Lattimore S, Akada M, Sunamura M, Prime W,
Campbell F, Brentnall TA, et al: Proteomic analysis of chronic
pancreatitis and pancreatic adenocarcinoma. Gastroenterology.
129:1454–1463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sabatino L, Fucci A, Pancione M, Carafa V,
Nebbioso A, Pistore C, Babbio F, Votino C, Laudanna C, Ceccarelli
M, et al: UHRF1 coordinates peroxisome proliferator activated
receptor gamma (PPARG) epigenetic silencing and mediates colorectal
cancer progression. Oncogene. 31:5061–5072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Unoki M, Kelly JD, Neal DE, Ponder BA,
Nakamura Y and Hamamoto R: UHRF1 is a novel molecular marker for
diagnosis and the prognosis of bladder cancer. Br J Cancer.
101:98–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
